0

Category: Diabetes

The Cardiometabolic Medicine Market: Future Outlook and Industry Trends 2021 

Delaying elective surgeries and routine health services, the COVID-19 pandemic is likely to have significant effects on medicine across a broad range of specialties, however, cardiometabolic medicine may experience these implications more acutely. As many risk factors – including heightened stress levels, increased sedentary lifestyles, and decreased physical activity – are currently being perpetuated by virus-related restrictions, these regulations may alter consumer and patient behaviors for years to come.

Nonetheless, the overall global cardiometabolic medicine market is forecasted to recover quickly and continue exhibiting upward movement. Despite the potential negative short-term repercussions of pandemic-adjusted medical care, a consistent rise in the prevalence of cardiometabolic diseases among the population is expected to propel growth within the industry in the coming decade.

Cardiometabolic Medicine Market Overview

Cardiometabolic disease and its associated comorbidities are among the most prevalent diseases worldwide; according to the American Heart Association, cardiovascular disease (CVD) accounts for approximately 1 out of 3 deaths in the United States and experts predict the total number of annual deaths attributable to CVD will exceed 23.6 million by 2030. Furthermore, researchers estimate that over half a billion individuals across the globe will be affected by obesity and diabetes by the year 2040.

Due to increased awareness and a greater availability of treatment options, some of these diseases no longer lead to fatal outcomes. As such, effective treatments are expected to contribute to market growth while research efforts focus on the development of new therapeutic options and subsidized pricing makes these drugs more accessible to a wider range of patients.

The cardiovascular drug market is anticipated to exhibit a compound annual growth rate of 3.8% to reach a value of $63.96 billion by 2026. At the same time, the global metabolic disorder therapeutics market size is expected to register a CAGR of nearly 8% growing to a value of approximately $89 billion in 2025. Key factors driving growth in the metabolic disorder sector is the increasing demand for one-time therapies and rising prevalence of lifestyle diseases.

Market Sectors and Their Driving Factors 

The Cardiovascular Drug Market 

One important sector of the cardiometabolic medicine market is expected to grow at a compound annual growth rate of 3% to ultimately reach a value of $106.1 billion by 2023. Fueled by an increased demand for effective therapeutics, upward movement in the cardiovascular drug market can be primarily attributed to the increased awareness of serious implications of CVD on human health. Improved understanding of cardiometabolic health as well as continued research and development efforts will contribute to the introduction of new therapeutics and technologies in the coming years, furthering industry expansion.

Additionally, the innovation and development of new therapeutics that target diseases more efficiently will fuel the upward trend in the cardiovascular drug market. At the same time, decreases in rates of cardiac surgeries and consultations due to re-scheduling, cancellations, no-shows, and COVID-19 restrictions are expected to sustain and potentially elevate demand for cardiovascular pharmacologic treatments as interim solutions.

The Obesity and Metabolic Disorder Sector 

Showing no signs of slowing own, the obesity epidemic will continue to drive rising industry value with the obesity treatment market forecasted to reach nearly $20 billion by 2026. While the United States maintains its position as the leader in obesity cases across industrial countries, cases of diabetes are steadily increasing are rising across the globe and putting many nations at risk for potential metabolic disorder epidemics.

As such, the metabolic disorder market sector is anticipated to continue its upward trend propelled by a rapidly aging population, increasingly sedentary lifestyles, rising cases of smoking and other metabolic pathway restricting practices, as well as heightened public awareness of these conditions and their long-term health consequences.

The Diabetes Drug Market

Diabetes has now become a global epidemic with over 5% of the population affected by the disease requiring constant medication. Current statistics indicate that approximately 34.2 million people in the United States have diabetes while many more remain undiagnosed and unaware of their condition. Alongside the rise in obesity, the growing adoption of a sedentary lifestyle and increasing consumption of unhealthy foods are likely to continue upward trends in prevalence and boost the diabetes drug market in the coming years.

North America currently generates the highest market revenue at approximately $24 million and is expected to dominate throughout the forecast period. However, Europe is anticipated to be the second most prominent region based on revenue by the year 2026. Market growth across the globe is likely to be fueled by the emergence of novel therapeutic products, including the insulin segment with more accessible therapeutics made available to patients. Growing investments in research and development spearheaded by government initiatives are anticipated to support the market sector and its rapid surge in the near future.

Established and Emerging Markets

The two leading players in the global cardiometabolic disease market are North America and Europe, the largest markets expected to hold their position as a result of high availability of skilled professionals and the presence of a large number of key market players in these regions.

Due to the high prevalence of cardiometabolic disease in China, the nation is expected to provide a significant market opportunity in the Asia Pacific region. This emerging market will boast increases and improvements in healthcare infrastructure, rising awareness about cardiometabolic health problems among the population, as well as growing demand for therapeutic options.

Additionally, major market vendors are increasingly seeking to expand their business geographically and in particular, in developing nations. Not only will this provide better medical care to people in developing nations but also provide growth incentives in the market, which will be fueled by mergers and acquisitions as well as investments in research and development during the coming years.

In addition to the aforementioned driving factors, the cardiometabolic medicine industry is also expected to benefit from the continued growth of the telemedicine sector in 2021 and beyond. Offering the opportunity for chronic disease management outside of the practice setting, telemedicine alongside various health technologies and tools are expected to fuel industry expansion as advances in digital infrastructure make these services more efficient and accessible to the general patient population. Despite potential challenges in the near-term, the cardiometabolic medicine market has a positive future outlook with significant growth projected in the forthcoming decade.

Understanding (and avoiding!) Microvascular and Macrovascular Complications

The blood vessels in your body are like the pipes running through your home. The whole vascular system is the pipeline through which blood travels, carrying oxygen and nutrients to tissues.

In turn, waste is moved away from the tissues to be metabolized and eliminated by the liver and kidneys. Blood vessels are bigger at their origin (the heart) and get progressively smaller (like the branches of a tree) as they extend to the farthest reaches of the body, such as your fingers and toes.

What Causes Macrovascular Disease?

Chronically high blood sugar, high cholesterol and high blood pressure (I like to call them The Big 3) cause damage to the walls of these ‘pipes’. High blood pressure and high cholesterol in particular can cause damage to the larger blood vessels – the vessels that supply the heart and the brain. This increases the risk for heart attack and stroke. We call this macrovascular disease.

The amount of damage that occurs depends on how high the blood pressure and cholesterol has been, and for how long. It’s fairly simple to understand if you think of the pipes in your home as an analogy. Over time the pipes in your house build up residue on their walls (remember those Roto-Rooter commercials on TV?) and when that happens, water doesn’t flow through optimally, and sometimes the pipes get completely blocked. It’s the same thing with large blood vessels. High blood pressure stretches and strains the blood vessel wall making it more susceptible to injury. High cholesterol can get into the wall of the blood vessels, causing them to thicken in areas called plaques. These plaques can rupture suddenly causing a clot to form and sudden blockage of the vessel – this is what happens in a heart attack. Blood flow to the tissues beyond is blocked and these tissues die because of lack of oxygen and nutrients.

What Causes Microvascular Disease?

On the other hand, the small blood vessels in the eyes, kidneys and nerves are more susceptible to the damaging effect of high blood sugar. This is called microvascular disease and leads to the more commonly recognized complications of diabetes – blindness, kidney failure and amputations. The reason behind these types of complications is slightly different but in the end, it’s basically because the blood vessels can’t get nutrients and oxygen to the places in our body that really need it. For example, say a person without diabetes is taking their dog out in the middle of the night and he slips on a partially wet Slip ‘N Slide that the kids left out in the backyard, and then he cuts his foot on an empty beer can strewn nearby. Not that big of a deal for your average Joe, but for someone with diabetes it could be a big problem if he also has vascular disease. Damaged or blocked small blood vessels prevent oxygen, nutrients and immune cells from getting to the cut in order to heal it properly.

Prevention is Possible

The good news (and there is good news!) is that these complications can all be prevented. Although it was long believed that controlling The Big 3 would reduce these complications, there wasn’t definitive proof in the form of well-designed clinical research until about 25 years ago.   However, since then there has been study after study documenting reduced rates of microvascular and macrovascular disease – and their complications – in diabetes by controlling these three risk factors.   We now have much better tools to treat The Big 3 – better drugs and better devices to monitor and treat diabetes, multiple classes of drugs to control blood pressure, and statins to keep cholesterol down.

What Every Person Living with Diabetes Should Know

Sometimes doctors get too focused on blood sugar and pay less attention to blood pressure and cholesterol. In my mind, every person living with diabetes is a candidate to take medications for The Big 3. The research is there to support doing so. There are some people living with diabetes who may not need treatment for all three, but they are definitely the minority. Your doctor will help sort out where you fit as an individual. There is a lot of misinformation on the internet about the safety of drugs and all drugs have some risk. Your doctor will assess the benefits and risks of each particular drug for your situation.

It’s also important to note that damage to blood vessels is silent in the early stages, very rarely are you even aware that it’s happening so make sure that your doctor routinely monitors you for potential vascular complications.

Here’s What You Can Do Now

In order to effectively monitor for vascular complications make sure you:

  1. Keep up on your regular and routine doctor visits
  2. Get your A1c checked two to four times per year
  3. Get an annual eye exam
  4. Ensure your doctor runs specialized blood and urine testing to evaluate your kidney function

For more info on the latest drugs, devices, and recommended preventative tests, check out the 5th edition of Dr. Edelman’s book Taking Control of Your Diabetes which you can get here. Early detection and treatment can prevent progression and sometimes reverse these complications.

The days of inevitable macrovascular and microvascular complications of diabetes are over. However, it takes some effort and education, and the best patient is an educated patient, so you are already one step ahead of the game.